Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
7
Neutral
2
Bullish
5
Bearish
7
Neutral
2
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Lupin is a global, innovation-led pharmaceutical company that develops and markets branded and generic formulations, biosimilars, injectables, inhalation products and APIs across 100+ countries, with particular strength in cardiovascular, diabetology, respiratory and anti-TB. The company combines a large India commercial footprint with a growing regulated-market presence in the United States and other developed markets.
Q3 FY26 was a company record: consolidated sales of INR 71,005 million (↑26% YoY), EBITDA of INR 22,095 million (↑62% YoY) with a 31.1% margin, and net income of INR 11,756 million (↑38% YoY); Lupin highlighted broad-based regional growth led by a USD 350 million quarter in the US, driven by Tolvaptan, Mirabegron and new product momentum.
Lupin is pivoting R&D and commercial strategy toward complex generics, injectables and biosimilars: the company announced US FDA approval for pegfilgrastim (Armlupeg™), has a rich pipeline of inhalation, injectables and biosimilars targeting multiple launches through FY28–FY31, and plans 10–15 ANDA filings in FY26 while targeting 100+ new product launches across platforms by FY31.
India remains a core growth engine with the Rx business growing 10.9% in Q3 FY26 and chronic therapies now ~67% of the portfolio; Lupin is building a semaglutide-focused division, expects to be a day-one participant in obesity/GLP-1 launches, and projects sustained outperformance of the domestic market through product launches and salesforce expansion.
Lupin is strengthening its ESG credentials while scaling complex product capability: the company achieved a 91/100 S&P Global ESG rating, CDP double A, SBTi approval for GHG targets and is advancing water recycling and zero-waste initiatives, underlining a simultaneous focus on sustainability, regulatory compliance improvements and quality remediation across manufacturing sites.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,13,215 Cr
Low Risk
21.2
36.2
0.3
5.0
2,492.00
1,838.65
Sales CAGR
Profit CAGR
ROE
ROCE
Lupin Ltd (LUPIN) is currently trading at 2,476.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Lupin is a global, innovation-led pharmaceutical company that develops and markets branded and generic formulations, biosimilars, injectables, inhalation products and APIs across 100+ countries, with particular strength in cardiovascular, diabetology, respiratory and anti-TB. The company combines a large India commercial footprint with a growing regulated-market presence in the United States and other developed markets. Q3 FY26 was a company record: consolidated sales of INR 71,005 million (↑26% YoY), EBITDA of INR 22,095 million (↑62% YoY) with a 31.1% margin, and net income of INR 11,756 million (↑38% YoY); Lupin highlighted broad-based regional growth led by a USD 350 million quarter in the US, driven by Tolvaptan, Mirabegron and new product momentum. Lupin is pivoting R&D and commercial strategy toward complex generics, injectables and biosimilars: the company announced US FDA approval for pegfilgrastim (Armlupeg™), has a rich pipeline of inhalation, injectables and biosimilars targeting multiple launches through FY28–FY31, and plans 10–15 ANDA filings in FY26 while targeting 100+ new product launches across platforms by FY31. India remains a core growth engine with the Rx business growing 10.9% in Q3 FY26 and chronic therapies now ~67% of the portfolio; Lupin is building a semaglutide-focused division, expects to be a day-one participant in obesity/GLP-1 launches, and projects sustained outperformance of the domestic market through product launches and salesforce expansion. Lupin is strengthening its ESG credentials while scaling complex product capability: the company achieved a 91/100 S&P Global ESG rating, CDP double A, SBTi approval for GHG targets and is advancing water recycling and zero-waste initiatives, underlining a simultaneous focus on sustainability, regulatory compliance improvements and quality remediation across manufacturing sites.
Over the past 52 weeks, Lupin Ltd has traded between a low of ₹1,838.65 and a high of ₹2,492.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Lupin Ltd has a market capitalization of approximately 1,13,215.35. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Lupin Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.23 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,13,215.35 Cr, Lupin Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Lupin Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Lupin Ltd is 21.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Lupin received an Establishment Inspection Report (EIR) with a satisfactory Voluntary Action Indicated (VAI) classification after an inspection held from April 13 to April 17, 2026.
Nanomi B.V., a wholly owned Lupin subsidiary, signed definitive agreements to acquire 11,794,497 shares representing a 43.38% stake in MPPI from existing shareholders.
Lupin received tentative US FDA approval for its ANDA for generic enzalutamide tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths.
The USFDA approved Lupin’s Armlupeg (pegfilgrastim-unne) 6 mg/0.6 mL injection in a single-dose prefilled syringe as a biosimilar to Neulasta (pegfilgrastim).
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Merger/Acquisition
Lupin Ltd: Nanomi B.V. completed acquisition of 11,794,497 shares of Multicare Pharmaceuticals Philippines, Inc. (MPPI) on 2026-07-01; MPPI completed buy-back of 61,118 shares and Nanomi's holding rose from 56.28% to 99.89%.
Product/Operations Update
Lupin Limited announced the EMA approved a change to NaMuscla's marketing authorisation adding 62 mg and 83 mg capsules and expanded indications to treat symptomatic myotonia in children (6-11 years, ≥20 kg), adolescents (12-17) and adults (≥18) with NDM.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1458.45 | 1,17,820 Cr | 30.37 | 3.42 | 0.89 | 11.27 | 14.95 | 9.11 | ||
1141.00 | 1,14,811 Cr | 22.78 | 4.23 | 0.09 | 18.59 | 17.35 | 9.59 | ||
1374.55 | 1,14,730 Cr | 27.34 | 3.01 | 0.58 | 11.07 | 12.54 | 7.15 | ||
2476.10 | 1,13,215 Cr | 21.23 | 5.04 | 0.73 | 23.76 | 24.88 | 13.96 | ||
2531.15 | 1,04,535 Cr | 54.65 | 6.41 | 0.04 | 11.74 | 13.13 | 6.90 | ||
1620.10 | 94,096 Cr | 26.85 | 2.48 | 0.25 | 9.25 | 11.76 | 5.99 | ||
1543.70 | 83,293 Cr | 93.72 | 15.72 | 0.13 | 16.77 | 16.14 | 8.47 | ||
| Median: 7 Co. | — | 1543.70 | 1,13,215 Cr | 27.34 | 4.23 | 0.25 | 11.74 | 14.95 | 8.47 |
